---
title: "Plerixafor - Multiple myeloma"
sidebar: mydoc_sidebar
permalink: db06809-mesh-d009101-1.html
toc: false 
---


Path ID: `DB06809_MESH_D009101_1`
{% include image.html url="images/db06809-mesh-d009101-1.png" file="db06809-mesh-d009101-1.png" alt="db06809-mesh-d009101-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C088327 | Plerixafor | Drug |
| UniProt:P61073 | C-X-C chemokine receptor type 4 | Protein |
| GO:0035701 | Hematopoietic stem cell migration | BiologicalProcess |
| CL:0000037 | Hematopoietic stem cell | Cell |
| MESH:D009101 | Multiple myeloma | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Plerixafor | DECREASES ACTIVITY OF | C-X-C Chemokine Receptor Type 4 |
| C-X-C Chemokine Receptor Type 4 | NEGATIVELY CORRELATED WITH | Hematopoietic Stem Cell Migration |
| Hematopoietic Stem Cell Migration | INCREASES ABUNDANCE OF | Hematopoietic Stem Cell |
| Hematopoietic Stem Cell | TREATS | Multiple Myeloma |
|---------|-----------|---------|

Comment: Plerixafor is used in combination with granulocyte-colony stimulating factor (G-CSF, filgrastim) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

Reference: 
  - [https://en.wikipedia.org/wiki/Plerixafor#Pharmacology](https://en.wikipedia.org/wiki/Plerixafor#Pharmacology)
  - [https://go.drugbank.com/drugs/DB06809](https://go.drugbank.com/drugs/DB06809)
  - [https://pubmed.ncbi.nlm.nih.gov/17640590/](https://pubmed.ncbi.nlm.nih.gov/17640590/)
